A year on, and Barr's Plan B is a huge success. The company is projecting sales of Plan B will double this year, reaching $80 million. The Rx to OTC switch (which will be discussed further in my upcoming Sept. 17 feature) turned into what was expected: a political issue that everyone needed to weigh in on. And yet, you have to say Barr (and organizations like Planned Parenthood) have done a better job at communicating the benefits than the critics have done at articulating the downside. In fact, I'm still not clear on the critics' main point of contention. I know they claim it's less effective than Barr asserts, but even if that's the case, their argument still seems to be limping along.